Lansoprazol +pharma

Lansoprazole, the active ingredient in Lansoprazol +pharma, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of reflux disease, ulcer conditions and Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazol +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage conditions involving excess gastric acid production. - Gastroesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation. - Peptic ulcer disease: promotes ulcer healing by lowering acid exposure. - Erosive esophagitis: reduces mucosal damage and supports tissue repair. - Helicobacter pylori eradication regimen: enhances antibiotic effectiveness by suppressing acid.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional upset stomach. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea, abdominal pain. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal liver function tests. - Acute interstitial nephritis: kidney inflammation, reduced urine output.

Before initiating therapy, consider the following precautions. - Assess renal function: adjust use in severe impairment. - Evaluate hepatic status: use with caution in liver disease. - Monitor long‑term use: assess bone health and magnesium levels. - Review concomitant medications: potential for drug‑drug interactions. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Lansoprazole may affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption, may compromise efficacy. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: reduced activation, diminishing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Methotrexate (high dose): increased serum levels, watch for toxicity. - Digoxin: modest increase in serum concentration, consider dose adjustment.